Jean-Marc Bellemin Net Worth

The estimated Net Worth of Jean Marc Bellemin is at least $1.27 Million dollars as of 3 September 2024. Mr. Bellemin owns over 23,438 units of Gritstone Bio Inc stock worth over $20,207 and over the last 6 years he sold GRTS stock worth over $0. In addition, he makes $1,245,560 as Chief Financial Officer and Executive Vice President at Gritstone Bio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Bellemin GRTS stock SEC Form 4 insiders trading

Jean has made over 3 trades of the Gritstone Bio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 23,438 units of GRTS stock worth $11,485 on 3 September 2024.

The largest trade he's ever made was exercising 23,438 units of Gritstone Bio Inc stock on 3 September 2024 worth over $11,485. On average, Jean trades about 6,114 units every 81 days since 2019. As of 3 September 2024 he still owns at least 41,239 units of Gritstone Bio Inc stock.

You can see the complete history of Mr. Bellemin stock trades at the bottom of the page.

Jean-Marc Bellemin biography

Jean-Marc Bellemin serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Bellemin has served as our Executive Vice President of Finance and Chief Financial Officer since January 2018. Prior to Gritstone, from January 2008 to December 2017, Mr. Bellemin served as senior vice president, market access, business solutions and services of Actelion Pharmaceuticals US Inc., or Actelion, a biotechnology company, until Actelion was acquired by Johnson & Johnson in 2017. Prior to Actelion, Mr. Bellemin held several financial leadership roles at Guerbet Group. Mr. Bellemin received a university degree in economics, a master’s degree in finance from Université Paris Dauphine, a postgraduate degree in finance and accounting from Université Paris II Panthéon-Assas and an M.B.A. from the ESSEC Business School in Paris, France.

What is the salary of Jean Bellemin?

As the Chief Financial Officer and Executive Vice President of Gritstone Bio Inc, the total compensation of Jean Bellemin at Gritstone Bio Inc is $1,245,560. There are 1 executives at Gritstone Bio Inc getting paid more, with Andrew Allen having the highest compensation of $2,187,440.

How old is Jean Bellemin?

Jean Bellemin is 48, he's been the Chief Financial Officer and Executive Vice President of Gritstone Bio Inc since 2018. There are 13 older and 5 younger executives at Gritstone Bio Inc. The oldest executive at Gritstone Bio Inc is Alan C. Mendelson J.D., 71, who is the Sec..

What's Jean Bellemin's mailing address?

Jean's mailing address filed with the SEC is C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070.

Insiders trading at Gritstone Bio Inc

Over the last 6 years, insiders at Gritstone Bio Inc have traded over $277,077 worth of Gritstone Bio Inc stock and bought 2,026,375 units worth $15,022,790 . The most active insiders traders include Group, Llc Green Jeremy Red..., Peter Svennilson, and Thomas Woiwode. On average, Gritstone Bio Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,654. The most recent stock trade was executed by Andrew R Allen on 15 May 2024, trading 24,263 units of GRTS stock currently worth $18,197.

What does Gritstone Bio Inc do?

gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.

Complete history of Mr. Bellemin stock trades at Iovance Biotherapeutics Inc and Gritstone Bio Inc

Gritstone Bio Inc executives and stock owners

Gritstone Bio Inc executives and other stock owners filed with the SEC include:

• Andrew Allen,
  President, Chief Executive Officer, Director
• Jean-Marc Bellemin,
  Chief Financial Officer, Executive Vice President
• Raphael Rousseau,
  Executive Vice President, Chief Medical Officer
• Karin Jooss,
  Executive Vice President - Research, Chief Scientific Officer
• Roman Yelensky,
  Executive Vice President, Chief Technology Officer
• Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.,
  Co-Founder, Pres, CEO & Director
• Erin E. Jones M.S.,
  Chief Operating Officer
• Steve Krognes,
  Independent Director
• Thomas Woiwode,
  Independent Director
• Richard Heyman,
  Independent Director
• Judith Li,
  Independent Director
• Nicholas Simon,
  Independent Director
• Elaine Jones,
  Chairman of the Board
• Vijay Yabannavar,
  Executive Vice President, Manufacturing and Technical Operations
• Erin Jones,
  Executive Vice President, Global Head of Regulatory Affairs and Quality Assurance
• Matthew Hawryluk,
  Executive Vice President, Chief Business Officer
• Alan C. Mendelson J.D.,
  Sec.
• Dr. Karin Jooss,
  Head of R&D
• Dr. Matthew Hawryluk,
  Exec. VP & Chief Bus. Officer
• Prof. Raphael F. Rousseau M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Stacy Proctor,
  Sr. VP & Head of People
• Rahsaan W. Thompson J.D.,
  Exec. VP & Gen. Counsel
• James Cho,
  Chief Accounting Officer
• Vassiliki Economides,
  Exec. VP & CFO
• Stephen W Webster,
  
• Group, Llc Green Jeremy Red...,
  
• Venture Capital V, L.P.Vers...,
  
• Peter Svennilson,
  Director
• Group Ii, Lp Column Group I...,
  
• Lifesciences Iii, L.P.Claru...,
  
• Rahsaan Thompson,
  EVP and General Counsel
• Shefali Agarwal,
  
• Clare Fisher,
  
• Naiyer Rizvi,
  
• Lawrence Corey,
  
• James Cho,
  SVP, CHIEF ACCOUNTING OFFICER
• Vassiliki Economides,
  EVP, CHIEF FINANCIAL OFFICER